Cytodyn Inc (CYDY)

[Northstar42]

The ASM Release is consistent with the Poster Presentation, but includes specific information I did not find on the Poster and vice versa. As I said in a prior post, I hope the company posts the complete Poster Presentation on the website. Here are a few more points mentioned in the Poster Presentation:

Anti-PRO 140 antibodies were not detected
Favorable PRO-140 PK profile that allows once-weekly dosing
No change in co-receptor tropism at virologic rebound

Safety Summary -
Generally well tolerated
No discontinuation due to AEs
No pattern of toxicity
Administration-site reactions were infrequent, mild
transient and self-resolving( in less than 10% of subjects)
No dose-limiting toxicity in preclinical or clinical studies.